Biggest News Aggregation in the World
📰 Two Part News

Two Part News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Two Part. Real-time updates on events, politics, business and more.

Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform

Intellectual property portfolio now includes 188 Patents and 131 Trademarks providing robust protection for the Company's product platforms ANN ARBOR, MI / ACCESSWIRE / May 2, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-ca...
Ann Arbor United States Larry Heaton Ashley Wood Zomedica Corp Research Development

: Gun control, then and now: GOP and NRA actions over AR-15s continue to stall progress

: Gun control, then and now: GOP and NRA actions over AR-15s continue to stall progress - This is part two of a two-part series on this history of gun control policy. You can read part one here. Part one of this series looked at how the Thompson submachine gun, popularly known as the Tommy gun, was originally developed as a weapon of war and then marketed to law enforcement agencies and the military.
Two Nbsp Of Two Part One Nbsp Of Series Nbsp Looked

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
United States San Antonio New Jersey East Hanover Isabella Zinck Thomas Hungerbuehler

Novartis Pharma AG: Novartis data highlight efficacy of Piqray in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline updates
United States San Antonio New Jersey East Hanover Isabella Zinck Thomas Hungerbuehler

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science